Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS

Next Previous
X
Search
Trial Profile

AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational
  • Acronyms GLITTER 2
  • Sponsors Gan&Lee Pharmaceuticals

    • Most Recent Events

    • 13 Oct 2023 According to a Gan&Lee Pharmaceuticals media release, data from this study were presented at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting.
    • 13 Oct 2023 Results presented in a Gan&Lee Pharmaceuticals media release.
    • 06 Oct 2023 Primary endpoint has been met. (Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top